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Little published information is available regarding epidemiological data on vitamin D status in the large geographical region of
Central Europe (CE). We searched the journal literature with regard to 25(OH)D concentrations among community-dwelling or
healthy people living in CE. 25(OH)D concentrations varied by age, season, study sample size, and methodological approach [i.e.,
25(OH)D assay used]. Concentrations of 25(OH)D in CE appeared lower than 30 ng/mL, and the magnitude of hypovitaminosis
D was similar to that reported in Western Europe. While most of the studies reviewed were cross-sectional studies, a longitudinal
study was also included to obtain information on seasonal variability. The longitudinal study reported wintertime 25(OH)D values
close to 21–23 ng/mL for all studied age groups, with a significant increase of 25(OH)D in August reaching 42 ng/mL for those
aged 0–9 years, but only 21 ng/mL for the elderly aged 80–89 years. The decrease in 25(OH)D with respect to age was attributed to
decreased time spent in the sun and decreased vitamin D production efficiency. Based on the literature review on vitamin D status
in the CE populations, it can be concluded that 25(OH)vitamin D levels are on average below the 30 ng/mL level.
1. Introduction
The literature published over the two last decades indi-
cates increasing awareness of vitamin D’s pleiotropic, multi-
directional action in the human body. Evidence from large-
scale studies contributed to the understanding that vitamin
D deficiency may be a significant risk factor for many
civilization diseases. There is recognized benefit of vitamin
D for bone health based on both observational studies and
randomized controlled trials [1]. There is also evidence
largely from cross-sectional, ecological, laboratory, and
observational studies that vitamin D reduces risk of many
types of cancer, cardiovascular disease, diabetes, autoimmune
and metabolic disorders, infectious diseases linked to
decreased immunity, and even some neuropsychiatric
disorders [2–8]. Based on the journal literature for the
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nonskeletal effects of vitamin D, it appears that serum
25-hydroxyvitamin D [25(OH)D] concentrations between
30 and 50 ng/mL are associated with significantly reduced
risk of such diseases [9–12]. Therefore, a variety of practical
and research activities are being undertaken worldwide to
evaluate vitamin D deficiency and improve vitamin D status.
In Central Europe (CE), researchers representing the region
developed recommendations to treat vitamin D deficiency
for Poland in 2009 [13] and for Hungary in 2012 [14]. Because
of convincing findings showing potential health benefits of
vitamin D, investigators in CE focus on determining serum
25-hydroxyvitamin D [25(OH)D] concentrations in the gen-
eral population and among different risk groups.This interest
inspired a conference, “Vitamin D—minimum, maximum,
optimum,” held in Warsaw, Poland, on October 19–20, 2012
(http://www.witaminad.waw.pl/).Themeetingwas organized
by the Children’s Memorial Health Institute, Department
of Biochemistry, Radioimmunology, and Experimental
Medicine, in Warsaw, with 550 attendees from European and
non-European countries. The conference sought to establish
recommendations on serum 25(OH)D concentrations
for Central Europeans. A related goal was to develop an
understanding of current serum 25(OH)D normative ranges
and of how they vary with respect to such factors as age, sex,
and season. The major purpose was to establish guidelines
for appropriate vitamin D supplementation for Central
Europeans of all ages in order to ensure adequate serum
25(OH)D concentration and, thereby, to guarantee short-
and long-term effects, with appropriate safety considerations.
The primary conclusion reached by the participants at the
Warsaw conference was consensus on optimal (target) serum
25(OH)D concentrations ranging from 30 to 50 ng/mL
(75–125 nmol/L). Although no convincing reports indicate
adverse health effects of serum 25(OH)D concentrations up
to 100 ng/mL (250 nmol/L), few studies show health benefits
associated with levels higher than 50 ng/mL.
2. Materials and Methods
This paper reviews the available spectrum of data on serum
25(OH)D concentrations in CE, compared with selected
findings from other European countries. We found several
articles through advanced searches of the National Library
of Medicine’s PubMed database and Scopus, using keywords
“vitamin D” or “serum 25-hydroxyvitamin D” along with
country names or “Europe.” Some of the CE “epidemiologic”
studies reported at the vitamin D conference in Warsaw
were also included for further analyses. Papers dealing with
healthy or community-dwelling people were included in
the tables, but people with diseases were not. However,
one set of data for patients was given in a separate table
because it provided longitudinal data on serum 25(OH)D
concentrations throughout the year [15].
3. Results
Tables 1–4 provide explicit comparative information on
serum 25(OH)D concentrations in Central European
countries as a function of age [16–46], whereas Table 5 gives
information as a function of season (monthly intervals)
stratified by age for a Hungarian population [15].
3.1. Neonates and Infants. Eight studies in this review
reported serum 25(OH)D concentrations for neonates and
infants in CE: one from the Czech Republic and seven
from Poland (Table 1). Mean serum 25(OH)D concentration
among neonates ranged between 7 and 24 ng/mL depend-
ing on season. Winter and spring values were low, 7–
14 ng/mL, whereas summertime values were better (19–
24 ng/mL). Recent Polish studies confirmed the above obser-
vations, showing higher summertime than winter/spring
mean 25(OH)D concentrations in the umbilical cord: 24.0 ±
8.5 ng/mL versus 13.5 ± 8.2 ng/mL (𝑃 < 0.001), respectively
[20–22]. Serum 25(OH)D values found in these studies
appeared lower than those recommended on the basis of a
recent randomized controlled trial of vitamin D supplemen-
tation during pregnancy.This study, performed by Hollis and
colleagues, demonstrated association between the 25(OH)D
level of 40 ng/mL and optimal serum 1,25-dihydroxyvitamin
D concentrations [47]. Fortunately, implementing recom-
mendations for neonates to start vitamin D supplementation
from the first days after delivery resolved, at least partly,
vitamin D deficiency during the first few months of life.
As Czech-Kowalska and colleagues showed, supplementing
neonates with daily doses of ∼550 IU of vitamin D increased
serum 25(OH)D to 55 ng/mL at the third month of life
[22]. Further, in the group of infants (𝑛 = 43) regularly
supplemented with a vitamin D dose of ∼1160 IU/day at both
the 6th and 12th month, 25(OH)D serum concentrations
unexpectedly decreased from 40.2 ± 18.8 ng/mL at the 6th
month to 32.0 ± 12.7 ng/mL at the 12th month (𝑃 < 0.01)
[17]. However, reduced daily vitamin D intake expressed in
international units/kilogram of body weight may account for
the observed decrease in 25(OH)D concentration [23].
3.2. Children and Adolescents. Table 2 shows serum
25(OH)D concentrations in children and adolescents.
In Central European countries, wintertime values ranged
from 9 ng/mL in Belarus [24] to 23 ng/mL in Hungary
[25]; summertime values ranged from 36 to 56 ng/mL. The
large winter range may be due to different 25(OH)D assays
used, which will be discussed later. In addition, studies with
smaller sample size may have been associated with variations
in 25(OH)D concentrations due to recruiting people who
may not have been representative of the larger population.
3.3. Adults. Table 3 presents serum 25(OH)D concentrations
for adults aged 20–60 years. In CE, wintertime 25(OH)D
concentrations ranged from 11 ng/mL in Poland to 18 ng/mL
in Estonia. Summertime 25(OH)D concentrations ranged
from 18 ng/mL in Ukraine to 35 ng/mL in Hungary, and
annual values found in larger studies (>100 cases) ranged
from 14 ng/mL inUkraine to 29 ng/mL in Belarus. InWestern
European countries of similar latitude, wintertime values
ranged from 13 ng/mL in Denmark to 20 ng/mL in Austria,
whereas those in summertime ranged from 23 to 35 ng/mL,
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Table 5: Serum 25(OH)D3 concentration (ng/mL) versus age range and month measured for patients at Semmelweis University, Budapest,
between April 2009 and March 2010 [9].
Month 0–9 years 10–19 20–29 30–39 40–49 50–59 60–69 70–79 80–89 SDD
March 25 23 23 23 22 22 23 23 20 4
May 31 23 25 24 23 24 24 21 21 21
June 30 26 30 30 28 26 29 28 21 56
July 35 30 33 31 28 27 27 25 19 55
August 42 37 35 35 36 29 33 25 21 42
September 36 30 30 29 30 29 26 26 16 18
October 31 23 23 27 24 24 23 20 15 9
November 23 23 25 26 27 23 27 26 23 2
December 22 22 21 21 21 19 23 20 15 1
and annual values were reported as 25 ng/mL in France [41].
Thus, 25(OH)D serum concentrations of Central European
and Western European countries showed consistent agree-
ment. Some information is available in the studies regarding
serum 25(OH)D concentrations in men and women. A study
from Great Britain involving 45-year olds in a cohort study
found that women had statistically higher concentrations
than men in winter, while men had statistically higher
concentrations in summer [42].The differences might be due
to men spending more time outdoors and women taking
more oral vitamin D. A study from Estonia found similar
but statistically nonsignificant results: in summer, men had
a mean serum 25(OH)D concentration of 24.2 ng/mL while
women had 23.4 ng/mL, while in winter the values for males
and females were 17.1 ng/mL and 17.8 ng/mL, respectively [32].
3.4. The Elderly. Table 4 gives serum 25(OH)D concentra-
tions for seniors aged 60 years or older. In Central European
countries, wintertime 25(OH)D concentrations ranged from
11 ng/mL in Ukraine to 20 ng/mL in Hungary. Summertime
25(OH)D concentrations ranged from 15 ng/mL in Ukraine
to 33 ng/mL in Hungary. Annual 25(OH)D concentrations
ranged from 13 ng/mL inUkraine to 29 ng/mL inHungary. In
Western European countries, wintertime values ranged from
17 to 20 ng/mL. Analyzing serum 25(OH)D concentrations
with respect to latitude in either Central orWestern European
countries revealed no consistent variability. At least in part,
the reasons for this could include that the solar ultraviolet-B
(UVB) dose gradient during European summer is not large
above 40∘N latitude and that skin pigmentation becomes
lighter as latitude increases, making it easier to generate
vitamin D from solar UVB [48]. As noted in Table 5, serum
25(OH)D concentrations decrease with age above about 50
years. Since most studies summarized in this table reported
25(OH)D concentrations for a limited range of ages, stated
in the table, the values in the table should be considered
representative of those for the age ranges studied and not for
those over the age of 60 years.
3.5. Effect of Age and Season. A useful study on the variation
of serum 25(OH)D3 concentration with respect to age in
10-year groupings and month of measurement (Table 5)
was reported for a population from Budapest, Hungary
(47.5∘N latitude, 16.8∘E longitude) [15]. Although the subjects
studied were patients, nothing indicated that their mor-
bidity affected serum 25(OH)D3 concentration. However,
the report noted that, for the 1307 subjects with repeated
measurements, serum 25(OH)D concentrations were lower
for the second measurement (26 ± 9 ng/mL) than for the first
(27 ± 13 ng/mL), suggesting that the medical staff did not
recommended taking vitamin D supplements. Table 5 gives
a summary of data from that study. Several months were
omitted for which serum 25(OH)D3 concentrations either
did not change or were inconsistent with concentrations for
other months; values in January were similar to those inMay.
Several associations become clear from the content of Table 5:
serum 25(OH)D3 concentration increased minimally before
June except for the population aged 0–9 years. For all
ages, serum 25(OH)D3 concentration started to decline in
September and reached wintertime values by October. Peak
serum 25(OH)D3 concentrations were the highest for the
youngest people and the lowest for the oldest people. The
wintertime mean serum 25(OH)D concentration was about
20–23 ng/mL for all ages. The increase in summer amounted
to 20 ng/mL for those aged 0–9 years, 14–15 ng/mL for those
aged 10–49 years, 10 ng/mL for those aged 50–69 years,
and 5–6 ng/mL for those aged 70–89 years. Two primary
factors accounted for age-related seasonal fluctuations (i.e.,
differences in summertime peak values): limited time spent
outdoors in sunlight and reduced efficiency of vitamin D
production from UVB irradiance. In a mid-1980s study,
vitamin D production efficiency reported for people older
than 60 years was about 25% of that for those younger than
20 years [49], owing to less 7-dehydrocholesterol in the skin,
which is converted to vitamin D3 through the action of
UVB irradiance followed by a thermal process. The change
in vitamin D production in summer as a function of age
agrees with the efficiency study.Those with darker skin make
vitamin D more slowly than those with light skin since the
melanin in the skin reduces the transmission of solar UVB to
the 7-dehydrocholesterol. In addition, Table 5 gives calculated
standard vitamin D doses (SDD) for whole-day irradiance
for solar UVBmeasured in Belsk, Poland (52∘N latitude, 21∘E
longitude) [50]. However, because vitamin D3 production is
limited to 10 000–20 000 IU/day (since UV both produces
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vitamin D and destroys its metabolites), one cannot use the
SDDvalues to estimate vitaminDproduction for a given time
in the sun. For such information, the graphs in the papers
by Webb and Engelsen [51] and Bakos and Miko´ [52] are
useful. Vitamin D production potential peaks near the end
of June, whereas serum 25(OH)D3 concentration peaks in
August. The lag of about 6 weeks is related primarily to the
time required to build up serum 25(OH)D concentration.
Serum 25(OH)D is the most important clinically available
measurement of vitamin D status, reflecting lifestyle and
dietary habits [53]. Determining the amount provided by
the sun or food is difficult. The duration and intensity of
exposure to sunlight are not easily measurable, and age, skin
pigmentation, sunscreens, clothing, and even window glass
reduce its effects [54]. In equatorial regions exposure to the
sun alone is adequate, but at latitudes above 40 degrees
north or south and higher, people make little vitamin D in
the winter. Measurement of serum 25(OH)D provides direct
information. Although its concentration depends on vitamin
D production and intake, its serum half-life is much longer
than that of vitamin D (weeks versus hours), and it therefore
provides an integrated assessment of vitaminD status. Serum
25(OH)D concentrations depend on age, sunlight exposure,
vitamin D dietary intake, or supplementation.
3.6. 25(OH)D Assays Used. The spectrum of methods com-
monly used in research and laboratory practice includes three
types:manual immunoassays, automated immunoassays, and
direct detection methods. Most instruments or approaches
yield reasonably accurate measurements; however, some
instruments appear problematic [44]. Several reports have
also discussed analogous pitfalls of the assays [55–59].
In a comparison of 25(OH)D assays in Sweden, a high-
pressure liquid chromatography (HPLC) assaymeasured 34±
2 ng/mL, a radioimmunoassay (RIA)measured 28± 2 ng/mL,
and a competitive immunochemiluminescence assay (CILA)
measured 24 ± 2 ng/mL [56]. In a comparison of assays with
liquid chromatography-tandem mass spectrometry methods
inAustralia,DiaSorin LIAISON, IDS, and Siemens assaysmet
minimum performance goals [59]. In a comparison study in
Warsaw, the Elecsys (total vitamin D) from Roche measured
about 2 ng/mL higher than the LIAISON from DiaSorin
[60]. Immunoassays are sensitive to 24,25-dihydroxyvitamin
D, which can occur at concentrations up to 5 ng/mL [61].
Vitamin D-binding protein concentrations also affect the
accuracy of serum 25(OH)D concentration measurement
[62]. Some laboratories validated their assay performance
by comparing measurements with samples submitted to
the international Vitamin D External Quality Assessment
Scheme (DEQAS) [58]. Comparability of 25(OH)D results
could be facilitated if all laboratories were to participate with
DEQAS.
4. Discussion
To our knowledge, this study is the first to summarize
available data regarding vitaminD status and epidemiology in
Central European populations of different ages. Most popu-
lations andmost age groups have at least a moderate deficit of
25(OH)D according to currently binding standard references.
The potential limitation we acknowledge is that all studies in
this review are either retrospective or cross-sectional. To draw
firm conclusions on intraindividual variations in 25(OH)D
levels in different seasons, a prospective study design would
be desirable. With the exception of two studies [43, 44], no
particular inclusion or exclusion criteria for study participa-
tion were assumptive; therefore, we recognize that studied
populations may have been heterogeneous. Furthermore,
25(OH)D3 and total 25(OH)D concentrations were usually
similar but not identical, so we analyzed results from studies
irrespective of type of vitamin D determination. A review
of 394 studies of unadjusted serum 25(OH)D concentrations
from around the world found a mean value of 22 ± 1 ng/mL,
with no effect of latitude for nonwhites [63]. However,
the regression fit to the data for white people went from
approximately 40 ng/mL near the equator to approximately
16 ng/mL at the poles. What happens in Europe is still
not clear from that paper. Evidently, skin pigmentation (as
well as diet at high latitudes) have adapted well to solar
UVB doses where people have lived for millennia [48].
A review of serum 25(OH)D concentrations among dark-
skinned people living in Europe—primarily those of African,
Asian, or Middle Eastern origin—supports this hypothesis.
These ethnically different groups had lower serum 25(OH)D
concentrations than the indigenous white inhabitants [64].
The three important factors contributing to the difference
were darker skin, clothing that covered more skin area, and
limited oral vitamin D intake from food. Serum 25(OH)D
concentrations in winter do not drop as low as might be
expected on the basis of solar UVB doses in winter for two
reasons: (1) the decay time of 25(OH)D is 4–6 weeks—that is,
the time it takes to drop to half its value—and (2) when serum
25(OH)D concentrations are low, the body converts vitamin
D to 25(OH)D much more efficiently [65].
The following question emerges: if the natural sources of
vitamin D that arrived at over millennia lead to mean annual
serum 25(OH)D concentrations slightly above 20 ng/mL,
why is this value not adequate? One point to be addressed
is that life expectancy has considerably increased in Europe
and elsewhere during the past century because of health
care advances that reduced the risk of dying from acci-
dents, digestive diseases, and respiratory and other infections
[66]. Europeans are therefore much more likely to die
now from cancer or cardiovascular disease. Ecological and
observational studies offer moderate evidence that vitamin
D reduces the risk of cancer [67–69] and cardiovascular
disease [70]. Thus, raising serum 25(OH)D concentrations
above 30–40 ng/mL should reduce mortality rates by about
15% and increase life expectancy by 2 years in Europe [71].
Although the above associations may be regarded cautiously
and require further long-term prospective investigation, it
is rather justified to recommend an individualized vitamin
D supplementation to all age groups in CE. The practical
approach of such a strategy is aimed to alleviate the vitamin
D status in this region—that is, to consequently diminish the
risk of 25(OH)D deficits.
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5. Summary and Conclusion
The essential finding in this review is that most people living
in both Central and Western Europe have serum 25(OH)D
concentrations below the optimal values of 30–50 ng/mL.The
main reason is that solar UVB, being the primary source of
vitamin D, is limited for most CE populations; thus, produc-
ing vitamin D from solar UVB from October through March
is nearly impossible above 40∘N latitude. By consequence,
the concentrations are particularly low fromOctober through
May, implicating the deficiency to a large extent [15]. Also,
most people spend most time indoors and so they produce
vitamin D only through casual sunlight exposure, which
raises mean serum 25(OH)D concentration from 15 ng/mL
in February to 30 ng/mL in September for individuals aged
45 years living in the UK [42]. The groups at particularly
high risk of vitaminDdeficiency include those largely staying
indoors, pregnant and nursing women, newborns, breast-fed
infants without vitamin D supplementation, overweight or
obese people [72], patients with chronic or infectious disease,
and those older than 50 years. A variety of preventive means
and interventions can be implemented in CE to increase
serum 25(OH)D concentrations, including increased but
reasonable solar UVB irradiance, fortification of food, and
augmented consumption of vitamin D supplements.
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